FIRST TRACKS BIOTHERAPEUTICS INC (TRAX)
Health Care · Clinical-stage antibody therapeutics · NASDAQ
Clinical-stage antibody-focused biotech advancing immune-modulating therapies for autoimmune and inflammatory diseases including celiac disease, eosinophilic esophagitis, and rheumatoid arthritis.
What FIRST TRACKS BIOTHERAPEUTICS INC does
First Tracks Biotherapeutics is a clinical-stage biotechnology company developing antibody therapies that modulate immune pathways for autoimmune and inflammatory diseases. The company's pipeline includes ANB033, a CD122 antagonist for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter for rheumatoid arthritis; and ANB101, a BDCA2 modulator.
Themes: ["Autoimmune/inflammatory disease therapy","Antibody therapeutics","Celiac disease","Eosinophilic esophagitis","Rheumatoid arthritis"]
Fundamentals
- Price$32.40 as of 2026-07-09 close
- Market cap$1.1B as of 2026-07-10
- 1-year return+70.5% as of 2026-07-09 close
- ROE-57.8% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta0.10 as of 2026-07-10
Key risks (from latest filing)
["Clinical development and regulatory approval risk: company's pipeline programs are in clinical development stages with uncertain timelines and regulatory outcomes.","Funding requirement risk: company may require additional financing or strategic investments to continue operations, with no assurance such funding will be available on acceptable terms.","Cash burn and liquidity risk: the company is pre-revenue with quarterly operating losses exceeding $50 million and declining cash reserves, requiring operational sustainability within available resources."]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.